UA83202C2 - Фенилзамещенные пиперидины для использования в качестве активаторов рапп - Google Patents

Фенилзамещенные пиперидины для использования в качестве активаторов рапп

Info

Publication number
UA83202C2
UA83202C2 UAA200505008A UA2005005008A UA83202C2 UA 83202 C2 UA83202 C2 UA 83202C2 UA A200505008 A UAA200505008 A UA A200505008A UA 2005005008 A UA2005005008 A UA 2005005008A UA 83202 C2 UA83202 C2 UA 83202C2
Authority
UA
Ukraine
Prior art keywords
cholesterol
phenyl substituted
piperidine compounds
substituted piperidine
compounds
Prior art date
Application number
UAA200505008A
Other languages
English (en)
Ukrainian (uk)
Inventor
Скотт Уильям Бегли
Томас Эндрю Брандт
Роберт Вейн Даггер
Уильям Эндрю Хада
Шерил Маерс Хейворд
Женгию Лиу
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of UA83202C2 publication Critical patent/UA83202C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Описываются активаторы РАПП альфа, фармацевтические композиции, которые содержат такие соединения, и применение таких соединений для увеличения уровней некоторых липидов в плазме, включая липопротеин высокой плотности-холестерол, и снижение уровней некоторых других липидов в плазме, таких как ЛНП-холестерол и триглицеридов, и соответственно для лечения заболеваний, которые усложняются низкими уровнями ЛВП-холестерола и/или высокими уровнями ЛНП-холестерола и триглицеридами, таких как атеросклероз и кардиоваскулярные заболевания, у млекопитающих, включая людей.
UAA200505008A 2002-11-26 2003-11-14 Фенилзамещенные пиперидины для использования в качестве активаторов рапп UA83202C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42950602P 2002-11-26 2002-11-26
PCT/IB2003/005235 WO2004048334A1 (en) 2002-11-26 2003-11-14 Phenyl substituted piperidine compounds for use as ppar activators

Publications (1)

Publication Number Publication Date
UA83202C2 true UA83202C2 (ru) 2008-06-25

Family

ID=32393563

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200505008A UA83202C2 (ru) 2002-11-26 2003-11-14 Фенилзамещенные пиперидины для использования в качестве активаторов рапп

Country Status (34)

Country Link
US (2) US7199243B2 (ru)
EP (1) EP1567493B1 (ru)
JP (1) JP4029091B2 (ru)
KR (2) KR100760055B1 (ru)
CN (1) CN100439337C (ru)
AR (1) AR042131A1 (ru)
AT (1) ATE425966T1 (ru)
AU (1) AU2003276596B8 (ru)
BR (1) BR0316521A (ru)
CA (1) CA2507465C (ru)
CO (1) CO5570701A2 (ru)
DE (1) DE60326752D1 (ru)
DK (1) DK1567493T3 (ru)
EA (1) EA008928B1 (ru)
ES (1) ES2321509T3 (ru)
GT (1) GT200300258A (ru)
HK (1) HK1083502A1 (ru)
HR (1) HRP20050437A2 (ru)
IS (1) IS7816A (ru)
MA (1) MA27532A1 (ru)
MX (1) MXPA05005583A (ru)
NL (1) NL1024881C2 (ru)
NO (1) NO20052921L (ru)
NZ (1) NZ539546A (ru)
PE (1) PE20040699A1 (ru)
PL (1) PL378268A1 (ru)
PT (1) PT1567493E (ru)
SI (1) SI1567493T1 (ru)
TN (1) TNSN05146A1 (ru)
TW (1) TW200424172A (ru)
UA (1) UA83202C2 (ru)
UY (1) UY28097A1 (ru)
WO (1) WO2004048334A1 (ru)
ZA (1) ZA200503104B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60326752D1 (de) * 2002-11-26 2009-04-30 Pfizer Prod Inc Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren
BRPI0511481A (pt) * 2004-05-25 2007-12-26 Pfizer Prod Inc uso
EP1765320A2 (en) * 2004-05-25 2007-03-28 Pfizer Products Incorporated Use of ppar agonists to treat ruminants
CN101014595A (zh) 2004-08-11 2007-08-08 杏林制药株式会社 新型环状氨基苯甲酸衍生物
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
JPWO2006101108A1 (ja) * 2005-03-23 2008-09-04 杏林製薬株式会社 新規環状アミノフェニルアルカン酸誘導体
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
RU2415846C2 (ru) * 2005-08-26 2011-04-10 Шионоги энд Ко., Лтд Производные, имеющие активность агонистов ppar-рецепторов
WO2007120605A2 (en) * 2006-04-11 2007-10-25 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
ES2357992T3 (es) * 2006-12-01 2011-05-04 Actelion Pharmaceuticals Ltd. Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina.
EP2178534A4 (en) * 2007-07-17 2011-03-30 Merck Sharp & Dohme SOLUBLE EPOXY HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSING METHODS
CA2691507C (en) * 2007-07-19 2016-06-21 H. Lundbeck A/S 5-membered heterocyclic amides and related compounds
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
FR2935510B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
FR2935511B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
UA107938C2 (en) * 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
US8716482B2 (en) * 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
TWI513695B (zh) * 2009-10-27 2015-12-21 Merck Sharp & Dohme （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物
EP2363825B1 (fr) 2010-03-04 2016-04-27 Inside Secure Procédé pour conduire une transaction au moyen d'un dispositif NFC
JP2014513923A (ja) 2011-03-04 2014-06-19 ファイザー・インク Ｅｄｎ３様ペプチドおよびその使用
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
RU2615769C2 (ru) * 2015-07-29 2017-04-11 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса" Средство для ингибирования фермента альфа-амилазы
US20220411372A1 (en) * 2019-09-20 2022-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small-molecule inhibitors for the b-catenin/b-cell lymphoma 9 protein-protein interaction
WO2024022521A1 (zh) * 2022-07-28 2024-02-01 南通环聚泰生物科技有限公司 靶向BCL9/β-连环蛋白互相作用的小分子化合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2025518A1 (ru) 1969-06-05 1970-12-10
US4476311A (en) 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
WO1993007141A1 (en) 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
WO1993012086A1 (en) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Arylamide derivative
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JP3233991B2 (ja) * 1992-06-26 2001-12-04 株式会社ソフィア 遊技機
EP0607536B1 (en) 1992-12-08 2001-01-24 Ss Pharmaceutical Co., Ltd. Arylamide derivatives
AU3138595A (en) 1994-07-20 1996-02-16 Acea Pharmaceuticals, Inc. Haloperidol analogs and the use thereof
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH09312086A (ja) * 1996-05-22 1997-12-02 Matsushita Electric Ind Co Ltd 光ディスク再生システム、光ディスク再生方法および光ディスク
WO1998005331A2 (en) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
IT1286497B1 (it) 1996-11-20 1998-07-15 Italfarmaco Sud Spa Difosfine di tipo misto eteroariliche-ariliche come leganti chirali, relativi complessi con metalli di transizione e impiego di detti
KR20010033355A (ko) * 1997-12-19 2001-04-25 폴락 돈나 엘. 아릴티아졸리딘디온 유도체
ATE273970T1 (de) 1998-04-16 2004-09-15 Pfizer Prod Inc N-acyl und n-aroyl aralkylamide
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CA2324330A1 (en) 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
JP2004507457A (ja) 2000-05-11 2004-03-11 協和醗酵工業株式会社 ２−ピペリドン化合物
BR0111206A (pt) 2000-05-22 2003-04-15 Aventis Pharma Inc Derivados de arilmetilamina para uso como inibidores de triptase
AU2001211337A1 (en) 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
KR20030043970A (ko) 2000-10-12 2003-06-02 에스에스 세야쿠 가부시키 가이샤 2,2-디페닐부탄아미드 유도체 및 이를 함유하는 의약
JP2002173426A (ja) 2000-12-05 2002-06-21 Ss Pharmaceut Co Ltd 血糖低下剤
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
EP1361878A1 (en) * 2001-02-15 2003-11-19 Neurosearch A/S Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
DE60326752D1 (de) * 2002-11-26 2009-04-30 Pfizer Prod Inc Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren

Also Published As

Publication number Publication date
UY28097A1 (es) 2004-06-30
TNSN05146A1 (fr) 2007-05-14
NO20052921L (no) 2005-08-18
TW200424172A (en) 2004-11-16
AR042131A1 (es) 2005-06-08
BR0316521A (pt) 2005-10-04
EP1567493A1 (en) 2005-08-31
PE20040699A1 (es) 2004-10-23
EA008928B1 (ru) 2007-08-31
JP4029091B2 (ja) 2008-01-09
KR20070063051A (ko) 2007-06-18
US20040157885A1 (en) 2004-08-12
DE60326752D1 (de) 2009-04-30
GT200300258A (es) 2004-11-30
MA27532A1 (fr) 2005-09-01
AU2003276596B8 (en) 2009-03-05
NZ539546A (en) 2007-11-30
CN1717389A (zh) 2006-01-04
EA200500629A1 (ru) 2005-12-29
US20070191429A1 (en) 2007-08-16
ES2321509T3 (es) 2009-06-08
KR100760055B1 (ko) 2007-09-18
AU2003276596B2 (en) 2009-02-12
CA2507465A1 (en) 2004-06-10
SI1567493T1 (sl) 2009-06-30
WO2004048334A1 (en) 2004-06-10
CA2507465C (en) 2009-04-28
HK1083502A1 (en) 2006-07-07
EP1567493B1 (en) 2009-03-18
PL378268A1 (pl) 2006-03-20
PT1567493E (pt) 2009-04-09
AU2003276596A1 (en) 2004-06-18
NL1024881C2 (nl) 2009-09-16
KR100875318B1 (ko) 2008-12-22
CN100439337C (zh) 2008-12-03
NL1024881A1 (nl) 2004-05-27
HRP20050437A2 (en) 2005-10-31
NO20052921D0 (no) 2005-06-15
JP2006509001A (ja) 2006-03-16
DK1567493T3 (da) 2009-06-08
IS7816A (is) 2005-04-20
MXPA05005583A (es) 2005-07-27
CO5570701A2 (es) 2005-10-31
US7199243B2 (en) 2007-04-03
KR20050086794A (ko) 2005-08-30
ATE425966T1 (de) 2009-04-15
ZA200503104B (en) 2006-12-27

Similar Documents

Publication Publication Date Title
RS20050395A (en) Ppar activators
UA83202C2 (ru) Фенилзамещенные пиперидины для использования в качестве активаторов рапп
AP2002002426A0 (en) Ppar agonists
TW200508222A (en) Quinoline and quinoxaline compounds
MXPA05012570A (es) Derivados de tetrahidroisoquinolina como activadores de ppar-a.
TW200736235A (en) Dibenzyl amine compounds and derivatives
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
TW200611690A (en) Substituted heteroaryl- and phenylsulfamoyl compounds
TW200610525A (en) Substituted heteroaryl-and phenylsulfamoyl compounds
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
AP2002002427A0 (en) Ppar compounds.
ATE301640T1 (de) Anellierte 4-carboxyamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp-hemmer
MX2007003441A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4- tetrahidroquinolina.
CA2282183A1 (en) Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
EA200700924A1 (ru) Соединения ряда дибензиламина и их производные
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
TW200745004A (en) Novel compounds, their preparation and use
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
TW200616964A (en) Quinoline compounds
EP1594509A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF IRRITABLE COLON SYNDROME AND NON ULCEREUS DYSPEPSIS
RS20080410A (en) Dibenzyl amine compounds and derivatives
WO2009027785A3 (en) 1, 3-oxazole derivatives as cetp inhibitors
UY29123A1 (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
DOP2002000331A (es) Compuesto de ppar